Home·Stocks·ADMA
ADMA Biologics, Inc.

ADMA

XNAS

ADMA Biologics, Inc.

Basic Materials · Biological Products, (No Diagnostic Substances)

$8.03
+0.05 (+0.63%)
15-min delayed

Drag to pan · Scroll to zoom · Hover for OHLC

Snapshot
Loading metrics…
About ADMA Biologics, Inc.

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Employees
647
Country
US
IPO Date
2013-10-17
www.admabiologics.com
COMMUNITY · $ADMA0 theses
POST YOUR TAKE →
Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…

Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.

ADMA ADMA Biologics, Inc. Stock — $8.03 +0.63% · AlgoThesis